ArticleExperimental & molecular medicine2026
Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic skin diseases, including atopic and contact dermatitis, are prevalent inflammatory disorders imposing clinical and socioeconomic burdens. Their pathogenesis involves impaired barrier function, genetic susceptibility and immune dysregulation, yet mechanistic insights remain limited by the lack of physiologically relevant human in vitro models. Conventional human skin organoids capture aspects of epidermal stratification but generally lack vascular components, limiting tissue maintenance and physiological relevance. To overcome these limitations, vascularized skin assembloids (VSAs) are generated by combining human induced pluripotent stem cell-derived skin organoids with blood vessel organoids under air-liquid interface conditions. This modular assembly supports the formation of key skin-like structural features, including a multilayered epidermis, organized dermal matrix and interconnected vascular-like networks associated with improved barrier maturation and dermal-vascular organization, while providing an accessible platform for epidermal allergen exposure and inflammatory analysis in a vascularized skin-like tissue context. Incorporation of immune cells establishes an immune-integrated and immune-responsive microenvironment that enables modelling of allergen-induced inflammation. Upon exposure to house dust mite extract, VSAs exhibit inflammatory remodelling with atopic dermatitis-relevant features, characterized by barrier disruption, keratinocyte stress responses, immune-cell infiltration and induction of type 2 mediators (IL-4, IL-13, TSLP, CCL17, CCL26). Treatment with clinically used atopic dermatitis therapeutics upadacitinib (JAK1 inhibitor) and dupilumab (IL-4Rα antagonist) improves barrier-associated features and suppresses STAT6-associated inflammatory signalling, showing responses consistent with their known mechanisms of action. Collectively, these findings support VSAs as a human-relevant, vascularized and immune-integrated skin assembloid model for mechanistic studies and preclinical evaluation of pharmacological responses in inflammatory skin diseases.
Identifiers
42816545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.